Challenges of COPD diagnosis

Expert Opinion on Medical Diagnostics

Volumn 7, Issue 6, 2013, Pages 543-556

  Price, David ^a   Brusselle, Guy ^b,c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Asthma; Case finding; Chronic obstructive pulmonary disease; Diagnosis; Differential diagnosis; Exhaled breath analysis; Phenotype; Screening

Indexed keywords

ALPHA 1 ANTITRYPSIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARBOCISTEINE; CORTICOSTEROID; FUEL; HISTAMINE; HYDROGEN PEROXIDE; IMMUNOGLOBULIN E ANTIBODY; ISOPROSTANE DERIVATIVE; LEUKOTRIENE; LEUKOTRIENE B4; METHACHOLINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NITRIC OXIDE; PEPTIDOLEUKOTRIENE; PHOSPHODIESTERASE IV INHIBITOR; PREDNISOLONE; THEOPHYLLINE;

AIRWAY OBSTRUCTION; ALLERGIC ASTHMA; ALPHA 1 ANTITRYPSIN DEFICIENCY; ASTHMA; BREATH ANALYSIS; BURN; CASE FINDING; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; COUGHING; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DYSPNEA; EARLY DIAGNOSIS; EMPHYSEMA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FRACTURE; HUMAN; HYPERINFLATION; OCCUPATIONAL EXPOSURE; PEAK EXPIRATORY FLOW; PHENOTYPE; PNEUMONIA; PREDICTIVE VALUE; RESPIRATORY AIRFLOW; REVIEW; RISK FACTOR; SCREENING; SMOKING; SPIROMETRY; TREATMENT RESPONSE;

ADULT; AGED; ASTHMA; BIOLOGICAL MARKERS; BREATH TESTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MASS SCREENING; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; RISK FACTORS; SPIROMETRY;

EID: 84887268632     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2013.842552     Document Type: Review

References (61)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD. Updated 2013. http://www.goldcopd.org/. [Accessed 14 August 2013]
2. World Health Organisation. Burden of COPD. Available from: http://www.who. int/respiratory/copd/burden/en/index. html [Accessed 14 August 2013]
3. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27:397-412
4. Calverley PM. COPD: early detection and intervention. Chest 2000;117:365S-71S
5. Wise RA, Tashkin DP. Preventing chronic obstructive pulmonary disease: what is known and what needs to be done to make a difference to the patient? Am J Med 2007;120:S14-22
6. Talamo C, de Oca MM, Halbert R, et al. Diagnostic labeling of COPD in five Latin American cities. Chest 2007;131:60-7
7. Peña VS, Miravitlles M, Gabriel R, et al. Geographic variations in prevalence and under diagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 2000;118:981-9
8. Hill K, Goldstein RS, Guyatt GH, et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ 2010;182:673-8
9. Pearson M, Ayres JG, Sarno M, et al. Diagnosis of airway obstruction in primary care in the UK: the CADRE (COPD and Asthma Diagnostic/ management REassessment) programme 1997-2001. Int J Chron Obstruct Pulmon Dis 2006;1:435-43
10. Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. J Asthma 2006;43:75-80
11. Melbye H, Drivenes E, Dalbak LG, et al. Asthma, chronic obstructive pulmonary disease, or both? Diagnostic labeling and spirometry in primary care patients aged 40 years or more. Int J Chron Obstruct Pulmon Dis 2011;6:597-603
12. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention.Updated 2012. Available from: http://www.ginasthma.org [Accessed 14 August 2013]
13. Soler-Cataluña JJ, Cosío B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 2012;48:331-7
14. Price DB, Yawn BP, Jones RC. Improving the differential diagnosis of chronic obstructive pulmonary disease in primary care. Mayo Clin Proc 2010;85:1122-9
15. Barnes PJ. Future treatments for chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc 2008;5:857-64
16. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease (update): full guideline CG101 London. Available from: http://www.nice.org.uk/cg101 [Accessed 14 August 2013]
17. Woolcock AJ, Anderson SD, Peat JK, et al. Characteristics of bronchial hyperresponsiveness in chronic obstructive pulmonary disease and in asthma. Am Rev Respir Dis 1991;143:1438-43
18. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005;128:2005-11
19. Panhuysen CI, Bleecker ER, Koeter GH, et al. Characterization of obstructive airway disease in family members of probands with asthma. An algorithm for the diagnosis of asthma. Am J Respir Crit Care Med 1998;157:1734-42
20. Jyrki-Tapani K, Sovijarvi A, Lundback B. Chronic obstructive pulmonary disease in Finland: prevalence and risk factors. COPD 2005;2:331-9
21. World Health Organisation. Alpha-1 antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ 1997;75:397-415
22. Tinkelman DG, Price DB, Nordyke RJ, et al. Symptom-based questionnaire for differentiating COPD and asthma. Respiration 2006;73:296-305
23. Price DB, Tinkelman DG, Nordyke RJ, et al. Scoring system and clinical application of COPD diagnostic questionnaires. Chest 2006;129:1531-9
24. Levy ML, Fletcher M, Price DB, et al. International Primary Care Respiratory Group (IPCRG) Guidelines: diagnosis of respiratory diseases in primary care. Prim Care Respir J 2006;15:20-34
25. National Heart Blood and Lung Institute. Expert Panel Report 3: guidelines for the Diagnosis and Management of Asthma. NIH Publication No 07 4051. Bethesda (MD). 2007. Available from: http:// www.nhlbi.nih.gov/guidelines/ asthma/asthsumm.pdf [Accessed 14 August 2013]
26. Soriano JB, Zielinski J, Price D. Screening for and early detection of chronic obstructive pulmonary disease. Lancet 2009;374:721-32
27. U.S. Preventive Services Task Force recommendation statement. Screening for chronic obstructive pulmonary disease using spirometry: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;148:529-34
28. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155:179-91
29. Sims EJ, Price D. Spirometry: an essential tool for screening, case-finding, and diagnosis of COPD. Prim Care Respir J 2012;21:128-30
30. van Schayck CP, Loozen JM, Wagena E, et al. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ 2002;324:1370
31. Martinez FJ, Raczek AE, Seifer FD, et al. Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS). COPD 2008;5:85-95
32. Price DB, Tinkelman DG, Halbert RJ, et al. Symptom-based questionnaire for identifying COPD in smokers. Respiration 2006;73:285-95
33. Price D. Spirometry and questionnaire use for early diagnosis of chronic obstructive pulmonary disease. Hot Topics Respir Med 2010;5(14):13-8
34. Grouse L, DeWeerdt S. editors. IPAG diagnosis and management handbook. chronic airways diseases.a guide for primary care physicians. MCR Vision, Inc; Edgewater: 2005
35. Buffels J, Degryse J, Heyrman J, Decramer M. Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. Chest 2004;125:1394-9
36. Thorn J, Tilling B, Lisspers K, et al. Improved prediction of COPD in at-risk patients using lung function pre-screening in primary care: a real-life study and cost-effectiveness analysis. Prim Care Respir J 2012;21:159-66
37. Sichletidis L, Spyratos D, Papaioannou M, et al. A combination of the IPAG questionnaire and PiKo-6 flow meter is a valuable screening tool for COPD in the primary care setting. Prim Care Respir J 2011;20:184-9
38. Jithoo A, Enright PL, Burney P, et al. Case-finding options for COPD: results from the Burden of Obstructive Lung Disease study. Eur Respir J 2013;41:548-55
39. Steenbruggen I, Zielinski J, Lange P, et al. A BOLD statement on how to case-find moderate/severe COPD. Eur Respir J 2013;41:503-4
40. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010;182:598-604
41. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012;7:e37483
42. Pistolesi M, Camiciottoli G, Paoletti M, et al. Identification of a predominant COPD phenotype in clinical practice. Respir Med 2008;102:367-76
43. Camiciottoli G, Bigazzi F, Paoletti M, et al. Pulmonary function and sputum characteristics predict CT phenotype and severity of COPD. Eur Respir J 2013;42:626-35
44. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008;32:962-9
45. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38
46. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/ salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations. Respir Med 2008;102:1099-108
47. Eltboli O, Brightling CE. Eosinophils as diagnostic tools in chronic lung disease. Expert Rev Respir Med 2013;7:33-42
48. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007;29:906-13
49. Liesker JJ, Bathoorn E, Postma DS, et al. Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD. Respir Med 2011;105:1853-60
50. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012;186:48-55
51. van de Kant KD, van der Sande LJ, Jobsis Q, et al. Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review. Respir Res 2012;13:117
52. Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352:2163-73
53. Corradi M, Majori M, Cacciani GC, et al. Increased exhaled nitric oxide in patients with stable chronic obstructive pulmonary disease. Thorax 1999;54:572-5
54. Maziak W, Loukides S, Culpitt S, et al. Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:998-1002
55. Clini E, Bianchi L, Pagani M, Ambrosino N. Endogenous nitric oxide in patients with stable COPD: correlates with severity of disease. Thorax 1998;53:881-3
56. O'Reilly P, Bailey W. Clinical use of exhaled biomarkers in COPD. Int J Chron Obstruct Pulmon Dis 2007;2:403-8
57. Chanez P, Vignola AM, O'Shaugnessy T, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997;155:1529-34
58. Papi A, Romagnoli M, Baraldo S, et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:1773-7
59. Beg MF, Alzoghaibi MA, Abba AA, Habib SS. Exhaled nitric oxide in stable chronic obstructive pulmonary disease. Ann Thorac Med 2009;4:65-70
60. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184:602-15
61. Antczak A, Ciebiada M, Pietras T, et al. Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive pulmonary disease. Arch Med Sci 2012;8:277-85